Eddie Hickman
Stock Analyst at Guggenheim
(4.32)
# 1,276
Out of 4,453 analysts
43
Total ratings
61.5%
Success rate
23.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics | Maintained: Buy | $25 → $29 | $13.08 | +121.71% | 7 | Jun 9, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $90 | $67.11 | +34.11% | 14 | May 7, 2026 | |
| ATAI AtaiBeckley | Reiterated: Buy | $11 → $16 | $4.17 | +283.69% | 2 | Apr 16, 2026 | |
| GHRS GH Research | Maintained: Buy | $29 → $34 | $24.60 | +38.21% | 4 | Mar 9, 2026 | |
| PMN ProMIS Neurosciences | Maintained: Buy | $125 → $35 | $10.24 | +241.80% | 4 | Feb 5, 2026 | |
| HELP Cybin | Maintained: Buy | $39 → $48 | $5.09 | +843.03% | 3 | Dec 3, 2025 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $1.68 | - | 7 | Aug 28, 2025 | |
| IMVT Immunovant | Reiterated: Buy | $44 | $38.22 | +15.12% | 2 | Aug 11, 2025 |
Zevra Therapeutics
Jun 9, 2026
Maintained: Buy
Price Target: $25 → $29
Current: $13.08
Upside: +121.71%
Tarsus Pharmaceuticals
May 7, 2026
Reiterated: Buy
Price Target: $90
Current: $67.11
Upside: +34.11%
AtaiBeckley
Apr 16, 2026
Reiterated: Buy
Price Target: $11 → $16
Current: $4.17
Upside: +283.69%
GH Research
Mar 9, 2026
Maintained: Buy
Price Target: $29 → $34
Current: $24.60
Upside: +38.21%
ProMIS Neurosciences
Feb 5, 2026
Maintained: Buy
Price Target: $125 → $35
Current: $10.24
Upside: +241.80%
Cybin
Dec 3, 2025
Maintained: Buy
Price Target: $39 → $48
Current: $5.09
Upside: +843.03%
Outlook Therapeutics
Aug 28, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.68
Upside: -
Immunovant
Aug 11, 2025
Reiterated: Buy
Price Target: $44
Current: $38.22
Upside: +15.12%